At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 120 enrolled
Drug / intervention
BI 1026706 +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase I Randomized, Double-blind, Placebo-controlled, Parallel-group Trial of BI 1026706 Administered Orally as Tablets Twice Daily for 4 Weeks to Patients With COPD in Order to Evaluate Safety, Tolerability, Pharmacokinetics and Effect on Inflammation
In Brief
A Phase 1 clinical trial evaluating BI 1026706 and Placebo for Pulmonary Disease, Chronic Obstructive. Completed, enrolled 120 participants across 10 sites in 4 countries.
Detailed Summary
The main objective of the current trial is to investigate safety, tolerability, pharmacokinetics and effect on inflammation of oral BI 1026706 administered twice daily for 4 weeks in patients with COPD.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPulmonary Disease, Chronic Obstructive
CountriesDenmark, Germany, Sweden, United Kingdom
Collaborators--
Timeline
Phase 1CompletedFinished
20162017201820192020202120222023202420252026
First PostedDec 2015
Enrollment StartJan 2016
Primary CompletionJun 2016
TodayJul 2026
First PostedDec 30, 2015
Enrollment StartJan 25, 2016
Primary CompletionJun 14, 2016
TodayJul 2, 2026
Enrollment to primary: 5 monthsPosted 10.5 years ago
Interventions
BI 1026706drug
Placebodrug
Placebodrug
For blinding purposes